Reality Check on Chemotherapy-Induced Nausea and Vomiting
Market access for chemotherapy-induced nausea and vomiting (CINV) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 25% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In March 2018, the FDA approved Teva Pharmaceutical Industries Ltd.’s 0.25 mg/5 mL generic palonosetron to prevent nausea and vomiting in adults that may occur after chemotherapy, as well as to prevent nausea and vomiting up to 24 hours after surgery. Its launch made it the first generic version of Eisai Inc.’s and Helsinn Healthcare SA’s injectable Aloxi on the market
- Key Findings: New entrants to this market have benefited from rapid uptake, driven both by clinical advantages and by favorable reimbursement dynamics. Merck & Co., Inc.’s Emend (aprepitant) and Aloxi (palonosetron hydrochloride) have the most favorable coverage compared with other brand name antiemetics
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.